Cytek Biosciences Form 4: 73k RSUs, 39k Options Awarded to Board Director

Rhea-AI Filing Summary

Cytek Biosciences (CTKB) filed a Form 4 disclosing new equity awards to independent director Richard Chin on 18 June 2025. The filing shows 73,289 Restricted Stock Units (RSUs) and 39,062 non-qualified stock options granted at an exercise price of $3.07 per share. No shares were sold.

The RSUs convert 1-for-1 into common stock once vested. Vesting spans three years, with 2/36 of the award vesting on 18 Aug 2025 and 3/36 vesting on each scheduled quarterly date thereafter until fully vested in August 2028. The stock options vest monthly at a rate of 1/36 over the same three-year period and expire on 17 Jun 2035, potentially adding another 39,062 shares to the float if exercised.

Following the grant, Chin holds all 112,351 derivative securities directly. The transaction represents routine director compensation and introduces a modest dilutive overhang but aligns the director’s incentives with shareholder value.

Positive

• No insider selling: the filing records only grants, signaling confidence rather than distribution.
• Incentive alignment: multi-year vesting ties director compensation to long-term share performance, viewed as a governance positive.

Negative

• Potential dilution: full vesting and exercise would add 112,351 shares to the float, though impact is immaterial relative to total shares outstanding.

Insights

Securities Analyst

TL;DR: Routine director equity grant; no sales; modest potential dilution, positive alignment.

The Form 4 reflects standard board remuneration: 73,289 RSUs and 39,062 options priced at $3.07. Vesting schedules reduce near-term share supply risk, and there is no insider selling signal. Assuming CTKB’s current basic share count (~>100 million), the additional 112k shares equate to <0.2%, thus immaterial to valuation. Nonetheless, equity-based pay ties director incentives to long-term performance, a mild governance positive. Investors should factor in small dilution in DCF/EP estimates but otherwise view the filing as neutral-to-slightly constructive.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chin Richard

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BOULEVARD

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/18/2025		A		73,289		(2)	(2)	Common Stock	73,289	$0	73,289	D
Director Stock Option (right to buy)	$3.07	06/18/2025		A		39,062		(3)	06/17/2035	Common Stock	39,062	$0	39,062	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2025; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2025 and each November 18 thereafter; 3/36 of the total shares underlying the RSU Award shall vest on March 10, 2026 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2026 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2026 and each August 18 thereafter, until fully vested.

3. 1/36 of the total shares subject to the option shall vest monthly over 3 years following the grant date of June 18, 2025.

	/s/ Valerie Barnett, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CTKB disclose in the latest Form 4?

Director Richard Chin received 73,289 RSUs and 39,062 stock options on 18 Jun 2025; no shares were sold.

What is the exercise price of the new CTKB director options?

The options carry an exercise price of $3.07 per share.

When do the CTKB RSUs for Richard Chin vest?

Vesting begins 18 Aug 2025 (2/36) with subsequent 3/36 tranches on specified quarterly dates until August 2028.

How many shares could be added to CTKB’s float from this grant?

A maximum of 112,351 shares (RSUs + options) if fully vested and exercised.

Did the CTKB director sell any shares in this filing?

No. The Form 4 reports only acquisitions via equity awards; there were no dispositions.